Background
Methods
Study population and collection of samples
Characteristics | Australia | Germany | ||||
---|---|---|---|---|---|---|
Group 1 | Group 2 | Group 3 | ||||
Mesothelioma | Controls | Mesothelioma | Controls | Mesothelioma | Controls | |
Total | 83 | 88 | 80 | 75 | 36 | 72 |
Histological subtype | ||||||
Epithelioid | 27 (32.5%) | 48 (60.0%) | 28 (77.8%) | |||
Sarcomatoid | 28 (33.7%) | 0 | 0 | |||
Biphasic | 28 (33.7%) | 12 (15.0%) | 4 (11.1%) | |||
Not specified | 0 | 20 (25.0%) | 4 (11.1%) | |||
Pathologic changes in controls | ||||||
Plaques | 88 (100%) | 55 (73.3%) | 0 | |||
Asbestosis | 0 | 0 | 44 (61.1%) | |||
Asbestosis and plaques | 0 | 20 (26.7%) | 28 (38.9%) | |||
Year of blood drawing | 2005 | 2006 | 2012 | 2012 | 2011 | 2010 |
Median (range) | (1996–2011) | (2000–2010) | (2011–2013) | (2011–2013) | (2008–2014) | (2009–2014) |
Age at blood drawing [years] | ||||||
Median (range) | 70 (53–84) | 69.5 (52–84) | 70 (41–89) | 72 (53–90) | 70 (34–85) | 71 (43–83) |
Calretinin storage time [months] | ||||||
Median (IQR) | 81.5 (42.9–111) | 59.8 (32.8–75.7) | 17.2 (7.4–23.2) | 19.3 (8.8–28.3) | 3.6 (1.9–7) | 10.9 (3.7–19.5) |
Mesothelin storage time [months] Median (IQR) | n.a. | n.a. | 21.3 (11.5–27.4) | 21.5 (11.1–30.4) | 7.5 (4.8–15.1) | 26.8 (19.1–31.9) |
Calretinin [ng/mL] | ||||||
N < limit of detection | 30 (36.1%) | 61 (69.3%) | 20 (25.0%) | 73 (97.3%) | 12 (33.3%) | 62 (86.1%) |
Median (IQR) | 0.79 (<0.28–1.70) | <0.19 (<0.09–0.63) | 1.10 (<0.48–2.16) | <0.01 (<0.01- < 0.08) | 1.01 (<0.33–1.74) | <0.20 (<0.08- < 0.34) |
P-valuea
| 0.0197 | <0.0001 | 0.0009 | |||
Mesothelin [nmol/L] | ||||||
N < limit of detection | 0 | 0 | 1 (1.25%) | 14 (18.7%) | 0 | 0 |
Median (IQR) | 2.65 (1.38–5.54) | 0.77 (0.53–1.08) | 4.06 (2.22–11.9) | 1.02 (0.46–1.45) | 2.01 (1.44–3.83) | 1.03 (0.73–1.21) |
P-valueb
| <0.0001 | <0.0001 | <0.0001 |
Determination of calretinin
Determination of mesothelin
Statistical analysis
Results
Discrimination of MM subtypes – Marker concentrations in sarcomatoid MM
Verification of the performance of calretinin and influence of country of origin on the markers
Individual and combined performance of calretinin and mesothelin to detect MM
Biomarker | False-positive rate | Cutoff | True positive | True negative | False positive | False negative | Sensitivity | Specificity |
---|---|---|---|---|---|---|---|---|
Calretinina[ng/mL] | 0.01 | 1.07 | 60 | 145 | 2 | 56 | 0.52 | 0.99 |
0.02 | 0.83 | 70 | 144 | 3 | 46 | 0.60 | 0.98 | |
0.03 | 0.68 | 78 | 142 | 5 | 38 | 0.67 | 0.97 | |
0.04 | 0.63 | 79 | 141 | 6 | 37 | 0.68 | 0.96 | |
0.05 | 0.58 | 82 | 139 | 8 | 34 | 0.71 | 0.95 | |
Mesothelinb[nmol/L] | 0.01 | 2.32 | 71 | 145 | 2 | 45 | 0.61 | 0.99 |
0.02 | 2.31 | 71 | 144 | 3 | 45 | 0.61 | 0.98 | |
0.03 | 2.15 | 76 | 142 | 5 | 40 | 0.66 | 0.97 | |
0.04 | 2.02 | 78 | 141 | 6 | 38 | 0.67 | 0.96 | |
0.05 | 1.99 | 80 | 139 | 8 | 36 | 0.69 | 0.95 |